Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: 'AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter.

Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer, the data from both of these studies will be presented during the ASCO plenary in June. We are also looking forward to seeing the results of several other important trials throughout the year.

At our Annual General Meeting we were pleased to announce a 7% increase in the annual dividend, and at our Investor Day on 21 May 2024 we will outline the evolution of our company, underscoring our confidence in sustaining industry-leading growth.'

Contact:

Tel: +44 (0)1223 344 800

Email: global-mediateam@astrazeneca.com

(C) 2024 Electronic News Publishing, source ENP Newswire